A Single-Center, Prospective Phase II Clinical Study of Proton Beam Intensity-Modulated Stereotac… (NCT07412327) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Single-Center, Prospective Phase II Clinical Study of Proton Beam Intensity-Modulated Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
China65 participantsStarted 2026-02-20
Plain-language summary
This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (AJCC eighth edition staging) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical proton hypofractionated radiotherapy. The prescribed dose for patients with peripheral lung cancer is 48-60Gy(RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. .Lung cancer confirmed by histology and/or cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after MDT discussion.
✓. The clinical staging based on PET-CT examination is: cT1\~3 N0M0, stage IA-IIB (AJCC eighth edition).
✓. Age: 18 years and above.
✓. KPS score ≥60.
✓. The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.
✓. Relatively good organ function:
✓. Normal bone marrow function: WBC≥3×109/L, Platelet ≥80×109/L, HGB≥90g/L